Ratings ABIONYX Pharma

Equities

ABNX

FR0012616852

Real-time Euronext Paris Other stock markets 04:28:25 2024-04-25 am EDT			5-day change	1st Jan Change
1.004 ^EUR	-3.46%		-6.52%	-22.05%

Mar. 14	Abionyx Pharma: to benefit from a 1ME grant from Bpifrance	CF
Mar. 11	Abionyx: reduced net loss in 2023	CF

Strengths

For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
For the past twelve months, EPS forecast has been revised upwards.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
One of the major weak points of the company is its financial situation.
Based on current prices, the company has particularly high valuation levels.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
ABIONYX PHARMA	-22.05%	35.79M	-
VERTEX PHARMACEUTICALS INCORPORATED	-1.51%	104B	B+
REGENERON PHARMACEUTICALS, INC.	+3.22%	97.42B	B+
ARGENX SE	+1.08%	22.2B	B
BIONTECH SE	-16.53%	21.23B	B+
GENMAB A/S	-8.70%	18.33B	A-
WUXI APPTEC CO., LTD.	-42.33%	16.35B	A-
BEIGENE, LTD.	-20.09%	15.06B	B
NEUROCRINE BIOSCIENCES, INC.	+5.47%	13.98B	C+
SAREPTA THERAPEUTICS, INC.	+28.85%	11.66B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes